Oppenheimer & Co. Inc. Increases Holdings in Moderna, Inc. (NASDAQ:MRNA)

Oppenheimer & Co. Inc. raised its stake in Moderna, Inc. (NASDAQ:MRNA) by 6.5% during the 2nd quarter, HoldingsChannel reports. The firm owned 42,931 shares of the company’s stock after acquiring an additional 2,626 shares during the quarter. Oppenheimer & Co. Inc.’s holdings in Moderna were worth $5,098,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Vanguard Group Inc. raised its holdings in shares of Moderna by 22.6% during the 4th quarter. Vanguard Group Inc. now owns 33,907,072 shares of the company’s stock valued at $3,372,058,000 after buying an additional 6,248,623 shares during the period. Norges Bank acquired a new stake in Moderna in the fourth quarter valued at approximately $347,565,000. Wellington Management Group LLP raised its stake in shares of Moderna by 28.8% during the fourth quarter. Wellington Management Group LLP now owns 7,225,579 shares of the company’s stock valued at $718,584,000 after purchasing an additional 1,614,460 shares during the period. Sumitomo Mitsui Trust Holdings Inc. lifted its position in shares of Moderna by 42.9% during the first quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,545,829 shares of the company’s stock worth $164,724,000 after purchasing an additional 463,960 shares in the last quarter. Finally, Matrix Capital Management Company LP purchased a new position in shares of Moderna in the fourth quarter valued at $45,150,000. Institutional investors and hedge funds own 75.33% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have commented on MRNA shares. William Blair reiterated a “market perform” rating on shares of Moderna in a report on Thursday, June 27th. HSBC raised Moderna from a “reduce” rating to a “hold” rating and set a $82.00 price target for the company in a report on Wednesday, August 28th. Bank of America cut their target price on Moderna from $130.00 to $110.00 and set a “neutral” rating on the stock in a research report on Friday. Barclays decreased their price target on shares of Moderna from $168.00 to $155.00 and set an “overweight” rating for the company in a research report on Friday, August 2nd. Finally, Hsbc Global Res upgraded shares of Moderna from a “moderate sell” rating to a “hold” rating in a research note on Wednesday, August 28th. One analyst has rated the stock with a sell rating, thirteen have issued a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, Moderna currently has a consensus rating of “Hold” and a consensus target price of $108.53.

Insider Buying and Selling at Moderna

In other Moderna news, President Stephen Hoge sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, June 17th. The shares were sold at an average price of $138.16, for a total value of $2,072,400.00. Following the sale, the president now owns 1,457,089 shares in the company, valued at $201,311,416.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, President Stephen Hoge sold 15,000 shares of the stock in a transaction that occurred on Monday, June 17th. The stock was sold at an average price of $138.16, for a total value of $2,072,400.00. Following the completion of the transaction, the president now directly owns 1,457,089 shares of the company’s stock, valued at approximately $201,311,416.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO James M. Mock sold 1,321 shares of the firm’s stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total value of $104,874.19. Following the completion of the sale, the chief financial officer now owns 8,600 shares in the company, valued at $682,754. The disclosure for this sale can be found here. Insiders sold 108,158 shares of company stock valued at $13,239,712 in the last ninety days. Company insiders own 15.70% of the company’s stock.

Moderna Stock Down 2.0 %

NASDAQ:MRNA opened at $68.28 on Friday. The firm has a market capitalization of $26.17 billion, a PE ratio of -4.36 and a beta of 1.67. Moderna, Inc. has a 52 week low of $62.55 and a 52 week high of $170.47. The company has a current ratio of 4.09, a quick ratio of 3.92 and a debt-to-equity ratio of 0.05. The stock has a 50 day moving average of $95.06 and a 200-day moving average of $111.79.

Moderna (NASDAQ:MRNA) last issued its earnings results on Thursday, August 1st. The company reported ($3.33) earnings per share for the quarter, topping the consensus estimate of ($3.47) by $0.14. The firm had revenue of $241.00 million for the quarter, compared to analyst estimates of $128.41 million. Moderna had a negative return on equity of 21.35% and a negative net margin of 116.18%. The firm’s revenue for the quarter was down 29.9% on a year-over-year basis. During the same period last year, the company earned ($3.62) earnings per share. Analysts predict that Moderna, Inc. will post -9.52 EPS for the current year.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.